Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) EV-to-EBITDA : 0.00 (As of Jun. 25, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Clarus Therapeutics Holdings's enterprise value is $0.00 Mil. Clarus Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-22.25 Mil. Therefore, Clarus Therapeutics Holdings's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for Clarus Therapeutics Holdings's EV-to-EBITDA or its related term are showing as below:

CRXWQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.29 Med: -1.31 Max: -0.89
Current: -0.96

During the past 2 years, the highest EV-to-EBITDA of Clarus Therapeutics Holdings was -0.89. The lowest was -20.29. And the median was -1.31.

CRXWQ's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 13.815 vs CRXWQ: -0.96

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-25), Clarus Therapeutics Holdings's stock price is $0.0003. Clarus Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $0.000. Therefore, Clarus Therapeutics Holdings's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Clarus Therapeutics Holdings EV-to-EBITDA Historical Data

The historical data trend for Clarus Therapeutics Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings EV-to-EBITDA Chart

Clarus Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

EV-to-EBITDA

-3.01

Clarus Therapeutics Holdings Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
EV-to-EBITDA	Get a 7-Day Free Trial			-	-7.69	-3.01	-2.47	-1.85

Competitive Comparison of Clarus Therapeutics Holdings's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarus Therapeutics Holdings's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's EV-to-EBITDA falls into.

Clarus Therapeutics Holdings EV-to-EBITDA Calculation

Clarus Therapeutics Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	0.000	/	-22.245
	=	0.00

Clarus Therapeutics Holdings's current Enterprise Value is $0.00 Mil.
Clarus Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.25 Mil.

Clarus Therapeutics Holdings (OTCPK:CRXWQ) EV-to-EBITDA Explanation

Clarus Therapeutics Holdings's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.0003	/	0.000
	=	N/A

Clarus Therapeutics Holdings's share price for today is $0.0003.
Clarus Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Clarus Therapeutics Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXWQ) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.